Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06433180

PHASE3

Study of Fecal Microbiota Transplantation (FMT) in Severe IBS Patients

Sponsor: Assistance Publique - Hôpitaux de Paris

View on ClinicalTrials.gov

Summary

The objective of this protocol is to evaluate the efficacy of fecal microbiota transplantation (FMT) using oral capsules containing frozen stools vs sham FMT on IBS severity score at 12 weeks in patients with severe irritable bowel syndrome refractory to conventional treatments.

Official title: A Prospective, Multi-center, Double Blind Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule Versus Placebo in Severe Irritable Bowel Syndrome (IBS).

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2025-07-01

Completion Date

2029-07-15

Last Updated

2025-06-27

Healthy Volunteers

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

Administration of fecal microbiota transplantation ( FMT capsules)

Oral, capsulized, frozen fecal microbiota transplantation FMT delivering approximatively 24 g of stools taken in one day in two separate meals. Administration of the FMT after colon cleaning.

DRUG

Administration of the sham (PLACEBO)

Oral, capsulized, frozen capsules without fecal matter but containing cryopreservation solution will be administered at the same volume and same time point as in the experimental group. Taken in one day in two separate meals. Administration of the sham after colon cleaning.

Inclusion Criteria: * Age ≥ 18 years and \< 75 years * IBS defined according to Rome IV definition (IBS-C, IBS-D or IBS-M) * Severe disease (IBS-SSS \>300) and refractory to at least two previous treatment strategies:among the following : anti-spasmodic and/or laxatives (polyethylene glycol) or anti-diarrheal drug (loperamide) according to transit subtype for one month, antidepressants for 2 months, probiotics (ALFLOREX, SMEBIOCTA, PROBIOLOG FLORVIS) for 1 month, hypnosis for 5 hypnosis sessions in two months, Cognitive Behavioral Therapies for 2 months, colestyramine for IBS-D patients for 1 month, ondansetron for IBS-D patients and for 1 month, ebastine for 2 months, L-glutamine (5g x3/day, for 2 months, Gelsectan for one month, Biofeedback for 15 sessions in IBS-C (3 months), Low FODMAP diet for 1 month, gluten free diet for 1 month, standard dietary advice from the NICE (UK) for 1 month, increase in physical activity. * Patient with health insurance (AME excepted) * Informed written consent * For women with childbearing potential, efficient contraception for the duration of the participation to the study Exclusion Criteria: * Other chronic gastrointestinal disease (celiac disease, inflammatory bowel disease) * participants if there is a reason to suspect an alternative diagnosis to the IBS complaints * Surgical intervention in the gastrointestinal region except for appendectomy, hernia repair, cholecystectomy and hemorroidectomy * Treatment preceding FMT with: antibiotics, antifungic or probiotics treatment \< 4 weeks, or factors that may affect the composition of intestinal microbiota * Abuse of alcohol or drugs * Pregnancy or breastfeeding * Participation in any other interventional study * Patients under legal protection. * Acute COVID-19 infection * Presence of systemic disease, immune deficiency or treatment with immune-modulators * Severe psychiatric disorder * Participants who were assessed as likely to be noncompliant (ie, not adhering to the tasks they were to perform as participants)

Locations (1)

Gastro-enterology department, Avicenne Hospital

Bobigny, France